Studying imlifidase in comparison to the standard of care in the management of highly sensitized kidney transplant patients.
Brief description of study
The purpose of this study is to demonstrate the efficacy and safety of imlifidase in comparison to the standard of care (SoC) in the management of highly sensitized transplant patients.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Kidney Transplant
-
Age: Between 18 Years - 70 Years
-
Gender: All
- Patients with Cronic Kidney Disease stage 5, highly sensitized with a cPRA of 99.9% or higher.
Updated on
09 Mar 2024.
Study ID: 850733
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting